%0 Journal Article
%T The Effect of Switching Patients with Symptomatic Benign Prostatic Hyperplasia from Tamsulosin 0.2 mg to 0.4 mg
%A Supadach Teawongsuwon
%A Sompol Pempongkosol
%J Open Journal of Urology
%P 110-113
%@ 2160-5629
%D 2013
%I Scientific Research Publishing
%R 10.4236/oju.2013.32021
%X <p class=\"MsoNormal\">
	<b><span lang=\"EN-US\">Objectives: </span></b><span lang=\"EN-US\">In 2010,
tamsulosin 0.2 mg (OD) was withdrawn from Thailand and replaced with tamsulosin
0.4 mg (OD). Therefore, we assessed the impact of this change on the patients,
at a men¡¯s health clinic, with lower urinary tract symptoms suggestive of
benign prostatic hyperplasia (LUTS/BPH). <b>Material and Methods: </b>Subjects
were 100 men with BPH who had been taking tamsulosin 0.2 mg as needed for at
least 3 months. The outcome measures were IPSS, AMS and IEFF5 scores and
uroflowmetry. Tolerability was evaluated on by adverse events. Changes from
baseline were assessed using the paired <i>t</i>-test. SPSS version 12.0 was
used for statistical analysis, with p
&lt;</span><span lang=\"EN-US\"> </span><span lang=\"EN-US\">0.05 considered significant. <b>Results: </b>The mean follow</span><span lang=\"EN-US\"> </span><span lang=\"EN-US\">up of
tamsulosin 0.2 and 0.4 mg were 20.23 and 10.56 months respectively. On
switching from tamsulosin 0.2 to 0.4 mg, mean IPSS score improved from 15.54</span><span lang=\"EN-US\"> </span><span lang=\"EN-US\">¡À</span><span lang=\"EN-US\"> </span><span lang=\"EN-US\">SD 1.25
to 14.13</span><span lang=\"EN-US\"> </span><span lang=\"EN-US\">¡À</span><span lang=\"EN-US\"> </span><span lang=\"EN-US\">SD 1.09 (p</span><span lang=\"EN-US\"> </span><span lang=\"EN-US\">=</span><span lang=\"EN-US\"> </span><span lang=\"EN-US\">0.034), Q max <st1:chmetcnv unitname=\"cm\" sourcevalue=\"15.91\" hasspace=\"True\" negative=\"False\" numbertype=\"1\" tcsc=\"0\" w:st=\"on\">15.91 cm</st1:chmetcnv><sup>3</sup>/sec ¡À</span><span lang=\"EN-US\"> </span><span lang=\"EN-US\">SD 1.36 to <st1:chmetcnv unitname=\"cm\" sourcevalue=\"16.69\" hasspace=\"True\" negative=\"False\" numbertype=\"1\" tcsc=\"0\" w:st=\"on\">16.69 cm</st1:chmetcnv><sup>3</sup>/sec ¡À</span><span lang=\"EN-US\"> </span><span lang=\"EN-US\">SD 1.52
(p</span><span lang=\"EN-US\"> </span><span lang=\"EN-US\">=</span><span lang=\"EN-US\"> </span><span lang=\"EN-US\">0.128), and nocturia 3.15 ¡À</span><span lang=\"EN-US\"> </span><span lang=\"EN-US\">SD 0.32 to 2.68 ¡À</span><span lang=\"EN-US\"> </span><span lang=\"EN-US\">SD 0.39 (p</span><span lang=\"EN-US\"> </span><span lang=\"EN-US\">=</span><span lang=\"EN-US\"> </span><span lang=\"EN-US\">0.015),
respectively. However IEFF-5 score and AMS score increased from14.78</span><span lang=\"EN-US\"> </span><span lang=\"EN-US\">¡À</span><span lang=\"EN-US\"> </span><span lang=\"EN-US\">SD 1.38
to 15.79</span><span lang=\"EN-US\"> </span><span
%K Tamsulosin
%K Benign Prostatic Hypertrophy (BPH)
%K Lower Urinary Tract Symptoms (LUTS)
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=31407